Kinetics of humoral response to ALK and its relationship with minimal residual disease in pediatric ALCL.
Mussolin
L
L
Bonvini
P
P
Ait-Tahar
K
K
Pillon
M
M
Tridello
G
G
Buffardi
S
S
Lombardi
A
A
Pulford
K
K
Rosolen
A
A
D000293:Adolescent; D000077548:Anaplastic Lymphoma Kinase; D000906:Antibodies / Q000097:blood; D000917:Antibody Formation; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007700:Kinetics; D017728:Lymphoma, Large-Cell, Anaplastic / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology*; D018365:Neoplasm, Residual / Q000175:diagnosis* / Q000276:immunology; D009687:Nuclear Proteins / Q000276:immunology; D000090243:Nucleophosmin; D015514:Oncogene Proteins, Fusion / Q000276:immunology; D011505:Protein-Tyrosine Kinases / Q000276:immunology*; D020794:Receptor Protein-Tyrosine Kinases
D000906:Antibodies; D009687:Nuclear Proteins; D015514:Oncogene Proteins, Fusion; D000090243:Nucleophosmin; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D011505:Protein-Tyrosine Kinases; D020794:Receptor Protein-Tyrosine Kinases